GASTROINTESTINAL STROMAL TUMORS
Clinical trials for GASTROINTESTINAL STROMAL TUMORS explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMORS trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug ripretinib takes on standard therapy for Hard-to-Treat GIST cancer
Disease control OngoingThis study tests a new drug called ripretinib against the current standard sunitinib in people with advanced gastrointestinal stromal tumor (GIST) whose cancer worsened or who couldn't tolerate the first treatment imatinib. About 453 adults from multiple countries will take eithe…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 17, 2026 02:14 UTC
-
New combo therapy offers hope for patients with resistant stomach cancer
Disease control OngoingThis study tests a new drug combination (bezuclastinib plus sunitinib) in 40 adults with advanced gastrointestinal stromal tumors (GIST) that worsened despite sunitinib treatment. The goal is to see if the combination can delay cancer growth. Participants take both drugs by mouth…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New hope for rare GIST mutations: regorafenib study targets stubborn tumors
Disease control OngoingThis study tests if the drug regorafenib can help control gastrointestinal stromal tumors (GIST) that have specific gene mutations (KIT exon 17, 18, or 14, or SDHB deficiency) after imatinib has stopped working. It includes adults with measurable, unresectable tumors. The main go…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo tackles resistant gut tumors in early trial
Disease control OngoingThis early-phase study tests a new drug (TAS-116) combined with imatinib in people with advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib alone. About 78 participants will receive different treatments to find the safest dose and see if the combo c…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC